PHF23-Related Prognostic Signature Modulates Immune Microenvironment and Promotes Tumor Malignancy in Glioma
International Journal of Molecular Sciences · 11.03.2026 · 27 (6) · 2570
DOI: 10.3390/ijms27062570 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.03.2026. Verfasst von Guoming Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China. Hauptthemen laut MEDLINE: Glioma, Tumor Microenvironment, Brain Neoplasms. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Gansu Province, Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital.
Abstract (Originalsprache)
Gliomas exhibit considerable molecular heterogeneity and immunological complexity, emphasizing the need for effective biomarkers and therapeutic targets. In this study, the Chinese Glioma Genome Atlas (CGGA-325/693) and The Cancer Genome Atlas (TCGA-LGG/GBM) cohorts were used to explore the pathological role of PHD finger protein 23 (PHF23) in gliomas. Machine learning algorithms were performed to construct a PHF23-related prognosis signature (PHF23-RPS). Our analysis revealed significant upregulation of PHF23 in high-grade gliomas, while the PHF23-RPS exhibited strong predictive performance (AUC = 0.853). Two molecular subtypes were identified; Cluster 2 was characterized as “inflamed yet immunosuppressive”. This subtype displayed a tumor mutational burden (TMB) paradox, where elevated TMB failed to translate into survival benefits due to extensive M2 macrophage infiltration and checkpoint-mediated immune exhaustion. Pharmacogenomic screening and molecular dynamics simulations identified Entospletinib as a potential candidate targeting this immunosuppressive barrier, showing a stable binding affinity (−7.7 kcal/mol). Functional assays, including in vitro experiments and in vivo experiments via a male BALB/c nude mouse orthotopic glioma model (n = 6/group), confirmed that PHF23 silencing inhibited glioma malignancy. Our results identify PHF23 as a critical oncogenic driver in glioma and support the PHF23-RPS for risk stratification. Entospletinib may offer a potential immunomodulatory option for high-risk gliomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
- Key Laboratory of Neurosurgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou 730030, China.
- School of Life Sciences, Lanzhou University, Lanzhou 730030, China.
ORCID-Profile: Xiaoqing Wang, Guoqiang Yuan
Förderung
- Natural Science Foundation of Gansu Province
- Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital
Zitieren
APA
Zhao, G., Wang, X., Yang, P., Feng, P., Dai, J., Niu, L., Yuan, G., & Pan, Y. (2026). PHF23-Related Prognostic Signature Modulates Immune Microenvironment and Promotes Tumor Malignancy in Glioma. International Journal of Molecular Sciences, 27(6), 2570. https://doi.org/10.3390/ijms27062570
Vancouver
Zhao G, Wang X, Yang P, Feng P, Dai J, Niu L, et al. PHF23-Related Prognostic Signature Modulates Immune Microenvironment and Promotes Tumor Malignancy in Glioma. International Journal of Molecular Sciences. 2026;27(6):2570. doi:10.3390/ijms27062570
BibTeX
@article{Zhao2026,
author = {Zhao, Guoming and Wang, Xiaoqing and Yang, Pengyu and Feng, Peng and Dai, Junqiang and Niu, Liang and Yuan, Guoqiang and Pan, Yawen},
title = {PHF23-Related Prognostic Signature Modulates Immune Microenvironment and Promotes Tumor Malignancy in Glioma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2570},
doi = {10.3390/ijms27062570}
}
EUVIMED